Oxford Nanopore announcement sets sequencing sector abuzz

@article{Eisenstein2012OxfordNA,
  title={Oxford Nanopore announcement sets sequencing sector abuzz},
  author={M. Eisenstein},
  journal={Nature Biotechnology},
  year={2012},
  volume={30},
  pages={295-296}
}
them appealing to Roche, who sees Illumina’s technology as a potentially powerful adjunct to their diagnostics business—especially as their own sequencing property, 454, recedes in importance in the market. Illumina has urged its shareholders to resist Roche’s offer of $44.50 per share, which remains well below the current stock value. “It’s validating that Roche sees our technology as valuable,” says Greg Heath, senior vice president of diagnostics at Illumina. “[But] the price point is… Expand
Illumina swallows PacBio in long shot for market domination
TLDR
In 2015 the company released the smaller and more affordable—but at $350,000, still not cheap—Sequel instrument, and the company now has a reputation for top-quality data, and however, the company has yet to capture meaningful market share. Expand
Startups use short-read data to expand long-read sequencing market
433 often confounded by long stretches of repetitive sequences or large structural rearrangements, making it difficult or impossible to assign locations for some reads and introducing errors. “99% ofExpand
1D Genome Sequencing on the Oxford Nanopore MinION
TLDR
This unit provides a representative protocol for carrying out human genome sequencing on the Oxford Nanopore MinION, and the rapid sequencing speed and low upfront instrument cost are features drawing interest in this device from the genomics community. Expand
lordFAST: sensitive and Fast Alignment Search Tool for LOng noisy Read sequencing Data
Motivation: Recent advances in genomics and precision medicine have been made possible through the application of high throughput sequencing (HTS) to large collections of human genomes. Although HTSExpand
Characterization of MinION nanopore data for resequencing analyses
TLDR
The study of error distribution showed that substituted, inserted and deleted bases are not randomly distributed along the reads, but mainly occur in specific nucleotide patterns, generating a significant number of genomic loci that can be misclassified as false-positive variants. Expand
Next generation sequencing in clinical diagnostics
Next generation sequencing (NGS) is a moniker used to represent multiple highthroughput or massively parallel nucleic acid sequencing technologies that have emerged since the mid 2000s. TheseExpand
Benchmarking of de novo assembly algorithms for Nanopore data reveals optimal performance of OLC approaches
TLDR
OLC can be considered as a favorable algorithmic framework for the development of assembler tools for Nanopore-based data, followed by de Bruijn based algorithms as they consume relatively less or similar run times as OLC-based algorithms for generating assembly, irrespective of the memory allocated for the task. Expand
Next generation sequencing methodologies--an overview.
TLDR
The importance of getting the basics right is presented, namely, how the best phenotyping in the clinical domain will provide a higher chance of a successful NGS experiment and how 3 million SNPs and indels can be reduced to a biologically plausible and experimentally manageable n≤50 gene variants. Expand
Darwin: A Hardware-acceleration Framework for Genomic Sequence Alignment
TLDR
A hardware-accelerated framework for genomic sequence alignment that, without sacrificing sensitivity, provides 125× and 15.6× speedup over the state-of-the-art software counterparts for reference-guided and de novo assembly of third generation sequencing reads, respectively. Expand
Application of next-generation sequencing technologies in virology
TLDR
An exciting era of viral exploration has begun, and will set new challenges to understand the role of newly discovered viral diversity in both disease and health. Expand
...
1
2
3
4
5
...

References

Performance comparison of whole-genome sequencing platforms
TLDR
This work sequenced the genome of an individual with both Illumina and Complete Genomics to a high average coverage, and compared their performance with respect to sequence coverage and calling of single-nucleotide variants, insertions and deletions. Expand